People

Riccardo Dentesano is listed in Friulia’s current public staff directory as Investment Manager. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Sarah Barbarossa is listed in Friulia’s current public staff directory as Investment Manager. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Alessandro Villatora is listed in Friulia’s current public staff directory as Senior Investment Officer. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Andrea Fioravanti is listed in Friulia’s current public staff directory as Senior Investment Officer - specialista mercato. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Roberta Terpin is listed in Friulia’s current public staff directory as Vice Direttore Investimenti. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Alessandra Ramani is listed in Friulia’s current public staff directory as Vice Direttore Servizi Corporate. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Andrea Cauzer is listed in Friulia’s current public staff directory as Direttore Servizi Corporate. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Claudia Filozof is published by aMoon as External Adviser. Physician and drug-development specialist whose biography describes Fortrea leadership in metabolic and liver diseases. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Marco Signori is listed in Friulia’s current public staff directory as Direttore Generale. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Isaac Devash is published by aMoon as Venture Partner. Helped establish Growth, Velocity and the8400HealthNetwork; brings international investment and business-development experience. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Federica Seganti is listed in Friulia’s current public staff directory as Presidente e Amministratore Delegato. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Samuel Moed is published by aMoon as Venture Partner. Former Bristol Myers Squibb corporate-strategy executive with global biopharmaceutical transaction and integration experience. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Michael Sherman is published by aMoon as External Adviser. Physician and healthcare consultant at Sherman Healthcare Solutions; own biography describes additional advisory work with RA Capital. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred. Current source-verified RA affiliation: Michael Sherman holds the source-published role of Advisor within RA Capital Management’s Raven group. Published academic qualifications: MD , MBA , MS , BA. Universities identified in the own biography: University of Pennsylvania, Harvard University, Yale University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Scott Stanford co-founded ACME in 2018 and is a Partner. He previously co-founded Sherpa Capital and Silicon Foundry. His background includes co-leading Goldman Sachs’s global internet investment banking practice in San Francisco and working at early-stage LookSmart before its public listing. He advises founders on enterprise adoption and commercial relationships. He studied Social Studies at Harvard College and earned an MBA at Harvard Business School. SEC filings distinguish his manager authority from any separate personal investment.

Bar Katzir is published by aMoon as Receptionist. Supports reception and operations following military service; no separate investment responsibility is inferred.

Mike Derrick, identified in ACME’s SEC filing as Michael James Derrick, is the firm’s Chief Financial Officer and Chief Compliance Officer. He previously held finance leadership positions at Sherpa Capital and Trident Capital and worked across private equity and venture finance at Thomas Weisel Partners, Trust Company of the West and Apax Partners. Earlier experience includes fund administration at Mourant and HSBC and accounting training at Ernst & Young in Jersey. Career fund totals describe prior organizations, not new ACME fundraising.

Karin Zaum is published by aMoon as Executive Assistant. Previously supported Bionic Stork executives and worked at Amdocs; holds an MBA from Heriot-Watt University.

Rebecca Peretz is published by aMoon as Executive Assistant. Supports Growth and Edge investment teams; previously coordinated development and donor activities at Hadassah Hospital.

Natalie Chazon is published by aMoon as Executive Assistant. Provides executive support to Yair Schindel and the finance/legal teams; has business and behavioral-sciences education.

Madiha Danish is ACME’s Assistant Controller. She contributes financial accounting, analysis and management expertise. Previously she was a senior consultant at Armanino LLP. She earned a bachelor’s degree in business management and international business at Northwood University; the current published biography describes ongoing CPA studies rather than an already earned credential.

Masha Sherman is published by aMoon as Operations Manager & Executive Assistant. Manages Boston office operations and supports Tomer Berkovitz; previously led operations at Valiantys.

Maayan Janus is published by aMoon as Marketing Communications Manager. Health communications professional with biology and business education, responsible for marketing content and communications.

Jenny Redling is ACME’s Chief of Staff, supporting leadership priorities, cross-team coordination and relationships with investors and founders. Her professional experience spans venture capital, corporate innovation and nonprofit organizations, including earlier work in fundraising for education and community initiatives. She studied politics and psychology at the University of San Francisco.

Keren Ditkovsky is published by aMoon as Bookkeeper. Experienced bookkeeping professional previously at Bright Machines; studied bookkeeping at Ruppin College.

Sarit Tannenbaum is published by aMoon as Assistant Controller. Accountant with prior EY technology and biotechnology assurance experience.

Hany Nada co-founded ACME in 2018 and is a Partner. He advises company leaders on global expansion, commercial strategy and transactions. He previously co-founded GGV Capital, served as a managing partner through October 2016 and remained a venture partner until 2018. Before GGV he worked in equity research at Piper Jaffray. His current ACME biography identifies board roles at AviaGames, Canopy, Forma.ai and Forte. He earned degrees in economics and political science at the University of Minnesota.

Nataly Lipovyak is published by aMoon as Senior Bookkeeper. Former Onyx Industries bookkeeping-team leader; holds graduate training in economics engineering.

Christian Tang-Jespersen is a Partner at ACME who advises growth-stage technology businesses. His operating experience includes international chief executive roles and leading Heptagon through growth and acquisition. He works with founders on scaling organizations, international expansion, transactions and exit planning. The manager describes a career spanning the United States, China, Singapore, Switzerland and Denmark; historical outside positions are not treated as current appointments without further evidence.

David Dubinsky is published by aMoon as Controller. Former Reznik Paz Nevo accountant whose background includes auditing business and investment financial statements.

Yodfat Melzer is published by aMoon as VP Finance. Manages tax, valuation, portfolio monitoring and transaction-structuring support.

Alex Fayette is a Partner at ACME focused on technically complex startups in aerospace and defense, next-generation computing, technology-enabled biology, physical AI, energy and materials. He helps founders connect engineering progress with commercialization and company building. His current manager biography identifies board involvement with Akash, Avia Games, Laurel, Replika, Sphere Semi, True Anomaly and Muon Space. Previously he worked in investment banking at J.P. Morgan and studied economics at Yale.

Gaby Hirsch is published by aMoon as VP Investor Relations. Leads investor relationships, marketing, communications and brand activities.

Noah Lasson is published by aMoon as Chief Compliance Officer & CISO. Oversees compliance and information-security programs for the healthcare investment platform.

Co-founder of BeyondOS, explicitly identified in the founder’s primary financing announcement. The company’s current own team directory also lists Ben Dickenson.

Co-founder of BeyondOS, explicitly identified in the founder’s primary financing announcement. The company’s current own team directory also lists Anton Gauffin.

Anthony Hill founded Adapdix, the predecessor to Aispire. He was its founder and CEO in its December 2020 issuer financing release; this historical CEO title is not asserted as his current role.

Skip Glass previously led URoam, served as COO of Kiva, and held a product role at Sybase.

Marc Sperschneider founded and leads X2 Equity and formerly was managing shareholder of MatriX Technologies.

Renee Sass previously held senior finance and strategy roles at NRG Energy and was a partner at Fairlead Advisors.

Paul McCafferty has co-founded two venture-backed companies and led engineering for large-scale data systems.

Cory Baldwin previously founded and led sensemetrics, acquired by Bentley Systems in 2021.

Osnat Tirosh is published by aMoon as Chief People Officer & Chief of Staff. Human-capital executive with experience advising technology-company leadership and managing organizational growth.

Aleda Johnson leads brand and development at ACME, working across communications, strategic partnerships and operating initiatives for the firm and its portfolio. Before ACME she spent five years in program and operations work at Atomic Venture Studio. She holds a bachelor’s degree in Liberal Studies from the University of Wisconsin, Whitewater.

Noam Waldoks is published by aMoon as Chief Legal Officer. Lawyer who helped form Growth as outside counsel in2018 and joined the platform in2020.

Irena Katsman is published by aMoon as Chief Financial Officer. Finance leader responsible for reporting, treasury and corporate finance, with experience at public and multinational businesses.

Aike Ho is a Partner at ACME focused on frontier health, where robotics, synthetic biology and engineering meet. She supports technologies that address difficult healthcare constraints and also considers selected consumer businesses. Her current manager biography identifies board work with Conceivable Life Sciences, Arya Health, Camber and Brightside. She graduated from Yale University. Her approach combines business guidance and support for founders building complex companies.

Shachar Elias is published by aMoon as Intern. Previously performed family-office real-estate and financial analysis; supports Growth market and investment research.

Sharon Feldman is published by aMoon as Analyst. Life-sciences community builder who founded the Jerusalem chapter of Nucleate Israel before joining the investment team.

David Esra is published by aMoon as Analyst. Physician trained at the University of the Witwatersrand; supports early-stage Velocity investments and the Alpha value-creation team.

Jeff Ekberg, legal name Jeffery David Ekberg, is brokerageFINOP in currentFINRA filings and ChiefFinancialOfficer of the separateBrooklandsadvisoryLP in2026FormADV. Brooklands’ own archived directory named him SeniorAdvisor followingTPG/Newbridge/Colony/KPMGroles. He is a CPA and studiedbusiness/accounting atCaliforniaStateUniversityLongBeach.

Daniel Sass is published by aMoon as Associate. Physician trained at the University of the Witwatersrand, with emergency-medicine practice experience in Cape Town.

Jill DeMayo, legal name Jill Ellen DeMayo, is ChiefComplianceOfficer of BrooklandsCapitalStrategiesBDLP in current2026 FINRA filings. The archived own directory also identified her as an IQ-EQ director with priorGreyline/VistaCompliance/FINRAexperience. Her brokeragecompliancerole isdistinctfromMollyUnderwood’sadvisoryLPcompliancerole.

Molly Underwood, legal name Molly Sager Underwood, is Chief Compliance Officer of BrooklandsCapitalStrategiesLP in its2026 FormADV. The archived own directory listed her as ChiefAdministrativeOfficer after CFO/COO roles at alternative managers and11 years at TPG. She is a CPA with accountingdegrees fromTexasA&M; currentunit-specificcompliancetitle isdistinguishedfromolderadministrativetitle.

Rey Mozer is published by aMoon as Associate. Physician with clinical and healthcare-strategy experience who evaluates later-stage medical and healthcare technologies.

Trey Parra was an Associate in Brooklands’ archived own directory focused on advisory and campaign execution after analyst roles at DirectAccessCapital and PlainsCapitalBank. He holds finance degrees from USC and OklahomaState. Current own firm LinkedIn corroborates affiliation; a newer seniority/title is not inferred from secondary databases.

Hagai Marmor-Kollet is published by aMoon as Associate. Life-sciences researcher with molecular diagnostics and therapeutics experience, including a platform leadership role at1E Therapeutics.

Maxwell Williamson, called Max Williamson in Brooklands’ archived own directory, was its Vice President focused on advisory and campaign execution. He previously worked at HiveAI and BankofAmericaMerrillLynch and studied economics/sustainability at Stanford. Current own firm LinkedIn identifies his affiliation but does not independently verify an updated title.

Adam Kotzen is published by aMoon as Principal. Former Credit Suisse investment banker specializing in corporate transactions; evaluates later-stage Growth investments.

Max Del Vento, legal name Maximiliano Del Vento, was Managing Director in Brooklands’ archived own directory, focused on US/LatinAmerican distribution and investor engagement after Centerbridge and PartnersGroup roles. FINRA CRD5348264 confirms Brooklands registration May2018 throughSeptember2025 and currently not registered. No present Brooklands employment is asserted.

Jinny Choi’s Brooklands own archived directory identifies her as Managing Partner and Co-Founder of Pacific Bridge Asset Management, an affiliate of Brooklands, after joining Brooklands in2016. Earlier work included Bridgewater, UBS, GE and Morgan Stanley. This is explicitly an affiliated/historical directory attribution rather than an invented current Brooklands employee title.

Patrick Rivers is published by aMoon as Portfolio Manager. Joined in2024 after biotechnology investment research at Aquilo Capital Management; works on public healthcare equities and private therapeutics.

Kirk Syme was identified as Partner in Brooklands’ own archived directory, focusing on project management and advisory services across asset classes. He previously worked at Weston Presidio and Morgan Stanley and studied at Georgetown and Berkeley Haas. A complete current operating roster is not published; this role is source-qualified as last confirmed.

Roy Wiesner is published by aMoon as Partner. Leads Velocity investments and the Roche Diagnostics StarFinder collaboration; own biography identifies IBEX Medical Analytics and Eleos Health board service.

Dan Carroll, legal name Daniel Ashton Carroll, co-founded Brooklands Capital Strategies after helping establish TPG’s Asian investment business. Its archived own bio lists Harvard economics and Stanford MBA education. Current2026 FINRA confirms Managing Partner at the brokerage, and the advisory affiliate reports him as Limited Partner. His personalboard/investingactivities are not automatically Brooklandsfundchecks.

Robert Shirley is named in the official NIH OCIO leadership directory as Director, Office of IT Architecture. The office supports NIH’s information technology, governance, data security and research infrastructure.

Peter McMillan co-founded Brooklands Capital Strategies following14 years at TPG, including capital formation across geographies and asset classes. Brooklands’ archived own directory identifies him as Managing Partner;2026 FINRA identifies him as brokerage CEO/Managing Partner and the advisory affiliate reports him as Limited Partner. His prior client/TPGfundraising experience is not Brooklands-ownedfundcapital.

Yaron Daniely is published by aMoon as General Partner & Head of aMoon Alpha. Scientist and healthcare executive who co-leads Velocity and heads the Alpha operating-support team.

Jason Hitchcock is named in the official NIH OCIO leadership directory as Director, Information Technology Policy Review Office. The office supports NIH’s information technology, governance, data security and research infrastructure.

Moshic Mor is published by aMoon as General Partner. Entrepreneur and former SPL WorldGroup chief executive who co-leads the early-stage Velocity strategy.

Craig Hayn is named in the official NIH OCIO leadership directory as Acting Chief Information Security Officer. The office supports NIH’s information technology, governance, data security and research infrastructure.

Joe Henke is named in the official NIH OCIO leadership directory as Acting Deputy Chief Information Officer; Acting Deputy Director, OCIO. The office supports NIH’s information technology, governance, data security and research infrastructure.

Yair Schindel is published by aMoon as Co-Founder & Managing Partner. Physician and healthcare entrepreneur who co-founded the platform with Marius Nacht; his own biography dates the founding to2017.

Maureen Falvella is named in the official NIH OCIO leadership directory as Chief Information Officer; Director, Office of the Chief Information Officer. The office supports NIH’s information technology, governance, data security and research infrastructure. The appointment took effect on 26 July 2026.

David M. Murray, Ph.D., is NIH associate director for prevention and director of its Office of Disease Prevention. The official ODP biography supplies the distinguishing middle initial M. This verified institutional identity is kept separate from an unrelated pre-existing blank David Murray record.

Jonathan Green is listed as director of the NIH Clinical Center on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Joni Rutter is listed as director of the National Center for Advancing Translational Sciences on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Wendy Weber is listed as director of the National Center for Complementary and Integrative Health on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Steven Schiff is listed as director of the John E. Fogarty International Center on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Raymond Jacobson is listed as director of the Center for Scientific Review on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Peter Joseph Embí is listed as director of the National Library of Medicine on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Courtney Aklin is listed as director of the National Institute of Nursing Research on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Amy Adams is listed as acting director of the National Institute of Neurological Disorders and Stroke on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment. Amy Bany Adams is the acting director of NINDS, as confirmed by the current institute leadership directory. An official January2026 workshop biography describes her transition to acting director in that month. Her earlier NINDS service includes founding and leading the Office of Neuroscience Communications and Engagement; she also directed NIDCR science policy and analysis. This enrichment preserves the existing AmyAdams NIH component identity and prior NIH role, rather than creating a second individual. Her genuine NINDS portrait was published in2022, separately from current leadership verification.

Monica Webb Hooper is listed as acting director of the National Institute on Minority Health and Health Disparities on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Andrea Beckel-Mitchener is listed as acting director of the National Institute of Mental Health on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Erica Brown is listed as acting director of the National Institute of General Medical Sciences on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Kyle Walsh is listed as director of the National Institute of Environmental Health Sciences on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Griffin Rodgers is listed as director of the National Institute of Diabetes and Digestive and Kidney Diseases on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Jonathan E. Burke is listed as director of the National Institute of Dental and Craniofacial Research on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Debara Tucci is listed as director of the National Institute on Deafness and Other Communication Disorders on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

John Gaitanis is listed as director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Bruce Tromberg is listed as director of the National Institute of Biomedical Imaging and Bioengineering on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

John Powers III is listed as acting director of the National Institute of Allergy and Infectious Diseases on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

George Koob is listed as director of the National Institute on Alcohol Abuse and Alcoholism on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Richard Hodes is listed as director of the National Institute on Aging on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Judy Cho is listed as director of the National Human Genome Research Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

David Goff is listed as acting director of the National Heart, Lung, and Blood Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Michael Chiang is listed as director of the National Eye Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Anthony Letai is listed as director of the National Cancer Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Ferdinand Grozema is professor of Optoelectronic Materials at Delft University of Technology. He became chair of NWO’s Science domain and an executive-board member on September 1, 2026, succeeding Jan de Boer. He studied chemistry in Groningen, earned his doctorate in Delft in 2003 and has researched molecular and materials properties for optical and electronic applications. He joined the domain board in 2023.

Guda van Noort is professor of Persuasion and New Media Technologies at the University of Amsterdam. She became interim chair of NWO’s Social Sciences and Humanities domain and an interim executive-board member on June 1, 2026, succeeding Antal van den Bosch. Her research examines digital media and persuasive communication. She has participated in the domain board since 2023.

Ena Voûte joined NWO’s executive board and became chair of its Applied and Engineering Sciences domain on March 16, 2026. She is a professor of industrial design engineering at Delft University of Technology, where she previously served as faculty dean and then pro vice rector for international affairs. Her earlier career included marketing and management roles at Unilever and Philips.

Jan de Boer is a professor of theoretical physics at the University of Amsterdam. He joined NWO’s executive board and chaired its Science domain from September 2020, after participating in the earlier FOM and NWO domain governance. Ferdinand Grozema succeeded him effective September 1, 2026. The executive-board directory retains his biography and portrait; it is qualified here as historical rather than current leadership.

Arfan Ikram is a physician, epidemiologist and professor who became president of ZonMw and a member of NWO’s executive board in August 2022. He also heads the Epidemiology Department at Erasmus Medical Center. His research has addressed dementia, stroke, brain ageing and life-course epidemiology, including the Rotterdam Study.

Anka Mulder is NWO’s vice president and executive-board portfolio holder for operations and finance. Before NWO she chaired Saxion University of Applied Sciences from 2018 and served as vice chair of Delft University of Technology’s executive board from 2013 to 2018. The official NWO directory also lists her chairmanship of Stichting Studielink and supervisory affiliation with Quantum Delta NL.

Marcel Levi is a physician and professor of medicine who has led the Dutch Research Council since April 2021. His second presidential term began April 1, 2026. He previously led Amsterdam Medical Center and University College London Hospitals and held academic leadership roles at the University of Amsterdam and University College London.

Onur Oztaskiran works in Design at Play Money. He has more than20 years of visual communication and product-design experience across finance, education, blockchain and AI. His employer biography describes product and growth work, and its team tagline identifies earlier founding-design work at Udemy and Writer.

Melissa Eder works in Marketing at Play Money. She is a bilingual marketer, entrepreneur and community builder with marketing and operations experience for investment platforms, helping explain emerging technology and investing to wider audiences.

Juliette Chevalier is Growth Engineer at Play Money. Her career includes software development, developer relations and Helicone AI. She co-founded Surge, a community for women in crypto, and Adult Camp for Latin American founders. Her own juliet.tech site corroborates the former-diplomat/software-engineer identity; the unrelated Dennis Aronov link on her employer card is excluded.

Tina Hashemnia leads Founder Success and Deal Flow at Play Money. Her employer biography describes prior venture-capital chief-of-staff work, accelerator operations across several cohorts and venture-scout experience supporting founders and fundraising.

Wasim Khamlichi leads Product and Engineering at Play Money and is described in the company’s own team tagline as founder and CTO. He built music marketplace Airbit through its acquisition and previously began his technical career at EDS. His background combines software engineering, creator marketplaces and music production.

Cheryl Kellond founded Play Money and serves as CEO. Her operating career includes early product launches, venture-backed startup building and a prior acquisition. Her own biography describes mentoring nearly200 founders and a personal angel portfolio of about50 companies; these are personal career figures rather than Play Money fund closes.

With previous buy-side experience in Private Equity and Equity Research, Vinícius brings an analytical approach to SaaSholic’s research and fundraising efforts, helping the firm deliver insights and connect capital to the region’s most promising SaaS founders.

With years of expertise in M&A and Asset Management, Pedro is focused on supporting new investments and providing hands-on assistance to portfolio companies across key strategic and operational areas.

According to our founders, William is their guardian angel. William focuses on leveraging his operational expertise and vast network to support our founders to bring home the capital they need.

Gus has been working on scaling software sales teams and developing GTM for a long time, and his goal is to help our portfolio companies hire, scale and accelerate their revenue growth.

With a background in entrepreneurship and deep experience in SaaS and VC, Diego's goal is help early stage startup CEOs to scale their businesses to global success.

Yassin leads deal sourcing and execution across North Africa. He brings experience across investment and technology, having previously worked at AfricInvest, Sequence Ventures, and Procter and Gamble. Earlier in his career, he founded Wasalny, an Egyptian mobility startup. Yassin holds a BEng with First-Class Honours in Mechanical Engineering from Coventry University.

Sola is an investment analyst with extensive experience in fixed-income research, financial valuation, competitor research, investment deal execution, accounting, and auditing. She has worked at different companies, including FCSL Asset Management, MBO Capital Management Limited, Aircom Nigeria Limited, and Adcem Healthcare Ltd. Currently at Ventures Platform Fund, Sola is responsible for sourcing, evaluating, and executing deals. She conducts research on various investment, reviews and analyzes industry, company, and third-party research for the Active portfolio, and prepares presentations to the Investment Committee at VP Fund.

Oluwaseyi Tomosori is a corporate communications professional with 7 years of experience in driving reputation management and other strategic communication priorities for global brands and organizations. She is currently a Communications Associate within the Platform and Networks practice at Ventures Platform, where she leads the firm’s strategic communications efforts while also fostering a thriving community amongst its portfolio companies.

Odunayo is an experienced accountant with over 7 years of professional experience in finance and accounting. She holds a BSc degree in Accounting from Wesley University in Ondo and is a chartered accountant with the Institute of Chartered Accountants of Nigeria (ICAN). Odunayo has a strong background in Budgeting, Financial planning and management, Financial reporting, Financial Analysis, and Accounting. She is detail-oriented, highly organized, and has excellent communication and analytical skills.

Moyosoreoluwa is a highly skilled Executive Assistant, Virtual Assistant, and Administrative Manager with over six years of experience providing comprehensive support to executives and managing client-focused office operations. She is goal-oriented, results-driven, and recognized for her exceptional ability to streamline administrative processes, optimize productivity, and ensure seamless executive support.Currently serving as an Executive Assistant and Administrative Manager at Ventures Platform Fund, Moyosoreoluwa expertly manages executive schedules, event coordination, and high-level administrative functions. She is highly regarded for her adaptability and efficiency in handling dual responsibilities, ensuring smooth day-to-day operations.

Kola is an established investor, insightful non-Executive director, and company chair who is passionate about seeing start-ups grow and improving the lives of ordinary Africans by democratising prosperity. He brings demonstrable success from leading investment in over 70 companies in Africa, India, and the US, including payments companies such as Paystack. He has established networks across the private sector, development partners, financiers, governments, and regulators.

Innocent Isichei is an accomplished policy professional with extensive experience working with stakeholders in both the public and private sectors across Africa. He currently serves as a Director at ACIOE Associates, where he assists clients in entering new markets in Africa. His role involves shaping policy discourse on critical issues, such as fostering the growth of the payment ecosystem in key African markets. Additionally, Innocent supports the regulatory and government engagement efforts of clients, enhancing their understanding of the policy environment in countries like Nigeria, Ghana, South Africa and Kenya. Innocent is also a Senior Policy Adviser to Paystack Payments and a Partner at Ventures Platform, one of Africa’s leading venture capital firms. He previously served as the Director of Policy for Paystack Payments, where he played a pivotal role in shaping the company’s strategic direction and regulatory compliance.

Ifeoma is an experienced Fund Operations Analyst, Growth Strategist, and Audit Analyst. She is currently working as a Fund Operations Analyst for Ventures Platform Fund, where she provides insight into fund operations procedures for prospective clients due diligence processes and retrieves and maintains records of portfolio statistics and other investment operations reporting for internal and external stakeholders. Ifeoma has also served as a Director of Growth and Strategy at Quayo Ecosense Limited, where she is responsible for defining the company's growth strategy, coordinating and executing growth plans, and optimizing the funnel to meet revenue targets.

Hafeez Bakare is published by Ventures Platform as Head, Finance and Fund Operations.

With over a decade of experience across fintech, global health, and social impact, Barry is a seasoned operator and strategist who brings rare depth and regional expertise to the firm. Her role will see her centrally placed in identifying and supporting transformative early-stage startups, particularly those building a low-carbon, inclusive, and prosperous future for the continent. Prior to joining Ventures Platform, Barry led business development in Francophone Africa for Taptap Send, one of the largest cross-border payment companies operating across Africa, Asia and Latin America. Through her leadership, the business achieved significant profitability through strategic partnerships. She also held pivotal roles at Zipline, where she negotiated national-level partnerships to expand access to essential health commodities.

Ezinne is an experienced Executive Assistant and manages Investor Relations at Ventures Platform Fund. With over seven years of experience at the company, she has demonstrated excellent skills in schedule management, event coordination, and investor experience. Prior to joining Ventures Platform Fund, Ezinne worked as a program associate at the TY Danjuma Foundation, where she gained experience in Project Management and Coordination, managing several projects across Nigeria. She also worked as a Human Resource Manager at the Corporate Affairs Commission. Overall, she has developed strong communication, organisation, and project management skills, which have enabled her to excel in her roles at Ventures Platform Fund.

Elo is the Founder and CEO at Terragon Group, the leading DATA and Marketing Cloud company in Africa, which helps Brands intelligently deliver more meaningful experiences to African consumers on mobile. For over 13 years he has steered the company through its evolution from a digital agency to Africa’s foremost SaaS (Software as a Service) company; with development of proprietary, patented technology solutions, successful acquisition of a software company in Bangalore in 2018 and strategic partnerships with global technology and indigenous companies including Meta, Microsoft, MTN, Nigerian Breweries etc.

Dotun is the General Partner at Ventures Platform, with extensive experience in entrepreneurship, investing, and C-level operations. His skill set includes venture investing, portfolio support, board management, startup fundraising, product development, innovation consulting, community building, local and remote team leadership, P&L oversight, and multichannel growth marketing for both startup and established organizations. Before joining Ventures Platform, Dotun served as Principal at Novastar Ventures Platform and Chief Commercial Officer at Moniepoint. In these roles, he provided leadership in fundraising, investor relations, strategic investment, and acquisition. Dotun has over 20 years of experience across various sectors, and as a Board Observer for Moniepoint, he worked with the company from 2021-2022 to establish its services as a leading financial technology provider for SMEs and consumers. He was also an Investor and Board Observer at Turaco from 2020-2021.

Dolapo is an Investor at Ventures Platform. She is responsible for driving the investment process end-to-end including functions such as Deal Sourcing, Due Diligence, Transaction Structuring, and Portfolio Management. She currently serves on the board of Termii and as a board observer for SunFi. She is also a Mentor at Google for Startups. She spent 5+ years as a Strategy Consultant for Accenture and Bain working on transformational projects across multiple countries in the Middle East and Africa (e.g. Nigeria, Ghana, South Africa, Seychelles, Saudi Arabia, UAE) where she supported multiple government ministries and the largest multinational corporations across Energy, Finance, Agriculture, Consumer goods, Telecommunications and Mining.

Desigan Chinniah, aka Dees or cyberdees, is a creative technologist. Dees has a portfolio of advisory roles and board positions. He invests early into diverse and underestimated minority founders.Dees has had two decades of dot-com check-ins*. His superpower is his global relationship network and the ability to embrace chaos and context switch in sub-50ms. Advisor: Cloaked + Interledger Foundation + TigerBeetle + Zama

Damilola Teidi is an ecosystem builder with 10+ years experience in the technology space in Africa, with most of that time spent supporting and facilitating access to capital for high-growth technology startups across different stages of growth. Damilola is currently the Head of Platform and Networks at Ventures Platform, where she leads a team focused on building and ensuring the effective delivery of expertise-driven post-investment support initiatives that create value for the fund’s portfolio companies.

Collins is a versatile and experienced professional with a passion for entrepreneurship and innovation. He has a diverse background, having worked with organisations such as Ventures Platform Foundation, Sail, Greativation Limited, and Dataville Research LLC. Currently, Collins serves as an Analyst at Ventures Platform Fund, where he builds the company's Portfolio Support platform to provide support to its portfolio companies at scale. He also supports the investment team in finding and funding mission-driven founders building exceptional solutions to some of Africa's biggest problems.

Telecoms and Fintech Executive with 12+ years of international experience, including 8 years in C-level roles leading growth, innovation, and transformation. As CEO of Orange Money Mali, Aicha led it to become Orange Group’s largest and top-performing financial institution. Previously, as the inaugural Chief Strategy and Innovation Officer at Orange Mali, she built and scaled a newly created department into a key decision-making hub.

Adebimpe Popoola is a seasoned People, Culture and Operations leader with experience spanning technology, venture capital, professional services, workforce solutions and high-growth businesses. Her expertise cuts across people strategy, HR service delivery, organisational development, workforce planning, performance management, culture transformation and regional operations.

Greg Yap is a life-science and healthcare investor named in Mission Bay Capital’s outside investment advisory committee. Menlo Ventures’ own current biography identifies him as partner focused on healthcare, novel therapeutic platforms and technology, having joined in2017. His earlier experience includes Illumina Ventures, startup founding, Roche diagnostics and Affymetrix. He studied molecular biology at Princeton and earned an MBA at Stanford. The Mission Bay affiliation is outside advice and does not establish a personal investment or fund employment.

His own current public professional profile identifies Singular as his employer.

Supports European founders with go-to-market strategy and international growth.

Supports founder and talent connections for Singular.

Finance professional at Singular; current self-profile confirms the employer but hides her exact title.

Leads Singular communications and marketing; separately advises startup VIOLA.

Singular investor named by the 2026 How to Web conference.

London-based Singular investor.

Invests at the intersection of AI, life sciences and frontier innovation.

Singular investor and its first employee; her own public posts verify current firm activity.

Technology investor focused on developer tools, security and infrastructure.

Singular co-founder and general partner, as identified by portfolio company Vibe.

Singular co-founder; current own legal page names him its UK compliance officer.

Leads Corundum Neuroscience’s lab-to-market venture-building and investment platform.

Sources neuroscience companies and academic research in the United States.

Creates science content for Corundum Corporation; published on the neuroscience group roster.

Reviews neuroscience research and previously studied healthy aging.

Supports neuroscience investment sourcing and diligence.

Life-sciences investment and commercialization specialist; previously worked at OurCrowd and Medison Ventures.

Neuroscience scientist with experience in psychiatric drug development and medical-device regulation.

Justin Merle, CPA, is an investor at Zebra Ventures. Zebra’s own2024 report identifies him as Tony Palcheck’s colleague in its corporate venture team; his current professional profile and own2026 Apera AI investment posts corroborate the ongoing affiliation. The named2023 industry profile records earlier EY strategy/transactions work; this prior career is qualified historical. His investing work includes automation, computer vision, industrial software and enterprise technologies.

Tony Palcheck is vice president of Zebra Ventures, as named in Zebra’s April29,2026 Apera AI investment announcement. Earlier own interviews describe his role leading the corporate venture portfolio after joining Zebra through the October2014 Motorola Solutions enterprise-business acquisition. Managing Director is a historically published title. His work spans enterprise automation, AI, analytics and strategic technology investing.

Xiaomei Wu (吳曉梅/吴晓梅) is a limited-partner owner of TianjinHaifengYinhuaInvestmentManagementPartnership, which a2025 HKEX issuer prospectus identifies as the general partner of WenzhouHaiyin and TianjinHaiyin investment partnerships. She is named alongside DongpingLi, YuquanWang and XinMa in that exact manager ownership disclosure. The primary filing establishes her legal affiliation, while accessible current first-party sources do not independently establish a full biography, exact operating executive title or appointment date. Secondary databases describe a founding-partner role, which is retained as a research lead rather than imported as unqualified current employment.

Dongping Li (李東平/李东平) is the general-partner owner of TianjinHaifengYinhuaInvestmentManagementPartnership, the disclosed general partner of WenzhouHaiyin and TianjinHaiyin investment vehicles. The2025 HKEX issuer prospectus names him alongside YuquanWang, XiaomeiWu and XinMa as the manager’s four owners. This primary evidence establishes his legal management capacity within the Haiyin ownership network; it does not independently disclose his complete career history, current payroll title or education. Secondary romanisation DongpingLee is treated as a discovery alias, without merging unrelated similarly named investors.

Xin Ma (馬昕/马昕) is a Haiyin Capital partner explicitly quoted in Neurala’s primary June2016 financing announcement. He described the commercial opportunity for AI technology enabling autonomous consumer products and the firm’s connections with manufacturers and technology companies in China. Neurala publishes his original named portrait. A2025 HKEX prospectus identifies MaXin as a limited-partner owner of TianjinHaifengYinhua, the manager of two Haiyin investment vehicles. The recent legal ownership corroborates the exact investment-network identity, while his historical operating partner title is not asserted to be a fully updated2026 employment roster.

Yuquan Wang (王煜全) is the founding partner of Haiyin Capital and chair of InnovationMap, according to his primary speaker biography and the affiliated company’s own published history. He founded Haiyin in2008, connecting technology investment with manufacturing and commercialisation between the UnitedStates and China. His professional biography describes earlier founding roles at Consultech in1995 and the China subsidiary of Frost&Sullivan in1998. His published education and industry commentary span science and global innovation. A2025 HKEX prospectus also identifies him as a limited-partner owner of TianjinHaifengYinhua, the general partner of WenzhouHaiyin and TianjinHaiyin investment vehicles. This ownership is distinct from personal financing checks.

Maryanne Senna MD is a published external PureTech collaborator, a dermatologist at Massachusetts General Hospital and an assistant professor at Harvard Medical School. PureTech identifies her as founder and co-director of the MGH Hair Loss Clinic.

Christopher Porter PhD is a published external PureTech collaborator and director of the Monash Institute of Pharmaceutical Sciences in Australia. PureTech’s Glyph platform links identify lymphatic drug-delivery research; no corporate employment is inferred.

Samantha Meltzer-Brody MD is a published external PureTech scientific collaborator and the Assad Meymandi distinguished professor and psychiatry chair at UNC Chapel Hill. The affiliation does not establish a corporate board role or individual investment.

Daniel Wheeland is named in the current NIH associate-director directory as Associate Director for Research Facilities. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Steven Paul MD is a published external PureTech scientific collaborator. PureTech identifies him as founder and board chair of Seaport Therapeutics. This supports the neuroscience affiliation without implying a PureTech directorship or individual investment. Seaport’s own biography identifies more than40years in neuroscience and molecular neuropharmacology, prior KarunaCEO/chair and research leadership,17years at EliLilly including president of LillyResearchLaboratories, and18years at NIH including scientific director of NIMH.

Jane Simoni is named in the current NIH associate-director directory as Associate Director for Behavioral and Social Sciences Research. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Neil Shapiro is named in the current NIH associate-director directory as Associate Director for Budget. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Michael A. Rogawski MD PhD is a published external PureTech scientific collaborator and professor of neurology and pharmacology at UC Davis. The academic neuroscience affiliation is recorded separately from corporate employment or board membership.

Phillip Osborne is named in the current NIH associate-director directory as Acting Associate Director for Administration. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Peter Kilmarx is named in the current NIH associate-director directory as Acting Director for International Research. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Marlies Wijsenbeek is a published external PureTech collaborator and chair of the Erasmus Medical Center interstitial lung disease program. PureTech identifies her as principal investigator of a study of disease progression in newly diagnosed progressive fibrosing interstitial lung disease.

Renate Myles is named in the current NIH associate-director directory as Associate Director for Communications and Public Liaison. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Paul Noble is a published external PureTech collaborator and chair of medicine at Cedars-Sinai. PureTech highlights his work on two late-stage pirfenidone trials in idiopathic pulmonary fibrosis. No corporate employment or investment is inferred.

Sean Mooney is named in the current NIH associate-director directory as Associate Director for Information Technology, Cyberinfrastructure and Cybersecurity. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Colleen McGowan is named in the current NIH associate-director directory as Associate Director for Research Services. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Toby Maher is a published external PureTech collaborator and professor and director of interstitial lung disease at USC Keck School of Medicine. PureTech highlights his Phase II pirfenidone trial in unclassifiable interstitial lung disease. This is an external scientific affiliation.

Kevin Flaherty is a published external PureTech collaborator and University of Michigan professor. PureTech highlights his work on the Phase III nintedanib trial in progressive fibrosing interstitial lung disease, published in NEJM. No employment or personal investment is inferred.

Katherine Klimczak is named in the current NIH associate-director directory as Associate Director for Legislative Policy and Analysis. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Lyric Jorgenson is named in the current NIH associate-director directory as Associate Director for Science Policy. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Vincent Cottin is a published external PureTech collaborator, professor at Université Claude Bernard Lyon and coordinator of rare pulmonary diseases at Louis Pradel Hospital. The company also identifies his editorial role at the European Respiratory Journal. This is an external research affiliation.

Susan Gregurick is named in the current NIH associate-director directory as Associate Director for Data Science. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Geri Donenberg is named in the current NIH associate-director directory as Associate Director for AIDS Research. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Bill Bradford is a published external scientific collaborator of PureTech and its Founded Entities. The company identifies him as a former InterMune senior vice president who developed pirfenidone for idiopathic pulmonary fibrosis. This affiliation does not establish PureTech employment or a personal investment.

Janine Clayton is named in the current NIH associate-director directory as Associate Director for Research on Women's Health. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Robert F. Kennedy Jr. is named by the National Institute on Drug Abuse as Ex officio, National Advisory Council on Drug Abuse (HHS Secretary). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

H. Robert Horvitz PhD is PureTech’s board observer, R&D Committee chair and external scientific collaborator. A Nobel laureate, he is an MIT biology professor, HHMI investigator and MGH neurobiologist. His company founding includes Epizyme, Mitobridge and Idun; the observer role is distinct from a board directorship. Gates Foundation scientific advisory biography: H. Robert Horvitz, Ph.D. Robert Horvitz shared the Nobel Prize in Physiology or Medicine in 2002. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT), an investigator of the Howard Hughes Medical Institute, neurobiologist (neurology) at the Massachusetts General Hospital, a member of the MIT McGovern Institute for Brain Research, and a member of the MIT Koch Institute for Integrative Cancer Research. Horvitz’s research, focused on the roundworm C. elegans, has helped define evolutionarily conserved molecular genetic pathways important in human biology and human disease, including a major cancer-gene pathway and the pathway responsible for programmed cell death, or apoptosis. He has received many honors and awards. Horvitz is a member of the board of trustees of the Massachusetts General Hospital and is chairman of the board of trustees of the Society for Science and the Public. He was president of the Genetics Society of America. He has served on many editorial boards, visiting committees, and advisory committees. Horvitz was an advisor adviser to the WHO Special Programme for Research and Training in Tropical Diseases. He was co-chair of the National Cancer Institute Working Group on Preclinical Models for Cancer, and a member of the National Human Genome Research Institute Advisory Council, the U.S. National Academies of Science and Institute of Medicine Committee on Guidelines for Human Embryonic Stem Cell Research, and the American Academy of Arts and Sciences Committee on Advancing Research in Science and Engineering. He also was a member of the advisory committee to the director of the National Institutes of Health, and he was a member of the council of the U.S. National Academy of Medicine. Horvitz has been a consultant to pharmaceutical, biotechnology, and venture capital companies.

Mark E. Von Zastrow is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Glenn A. Tapia is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Kiran Mazumdar-Shaw is PureTech’s independent non-executive director and the founder of Biocon. Her published biography identifies MIT trusteeship, National Academy of Engineering membership and roles at Infosys and Narayana Health. She studied zoology at Bangalore University and malting and brewing in Australia and received the Padma Shri and Padma Bhushan.

Angela R. Laird is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Kevin Gray is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

John LaMattina PhD is PureTech’s independent non-executive director, serving since 2009. He previously led Pfizer Global Research and Development during a 30-year Pfizer career and is a pharmaceutical research author. He studied chemistry at Boston College and the University of New Hampshire and conducted NIH postdoctoral research at Princeton.

Cristiane S. Duarte is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Michele Holcomb PhD is PureTech’s independent non-executive director and Audit Committee member. Her healthcare strategy career includes leadership at Cardinal Health, Teva and McKinsey. She holds chemistry degrees from Stanford and Berkeley and previously worked as a research chemist at Ciba-Geigy and Syntex.

Sandra D. Comer is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Deborah Chassler is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sharon Barber-Lui is PureTech’s published interim board chair and Audit Committee member. Her finance career includes Teva’s North America CFO role, EQRx and more than 20 years at Merck, after starting at KPMG. She earned undergraduate and MBA degrees at Lehigh and is an AICPA member.

Katherine L. Beebe Devarney is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Arpana Agrawal is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Allison Mead Talbot is PureTech’s senior vice president of communications, responsible for corporate and internal communications and investor and media relations. Before joining in 2016 she worked at TogoRun/FleishmanHillard and Feinstein Kean Healthcare/Ogilvy. Her experience includes regulatory launches, transaction communications and corporate branding.

Ivan Montoya is named by the National Institute on Drug Abuse as Acting Director, Division of Therapeutics and Medical Consequences. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Tristan McClure-Begley is named by the National Institute on Drug Abuse as Acting Director, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Susan R. B. Weiss is named by the National Institute on Drug Abuse as Director, Division of Extramural Research; Executive Secretary, NACDA. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Charles (Chip) Sherwood JD is PureTech’s chief operating officer and general counsel, overseeing strategy, operations, governance and compliance. He joined in August 2021 after leading corporate legal work at Anika Therapeutics. He earned degrees at Middlebury and Vanderbilt and is admitted to the Massachusetts Bar.

Landhing Moran is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Center for Clinical Trials Network. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Candace Webb is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Angela Lee-Winn is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Michael Inbar CPA MBA is PureTech’s chief accounting officer, overseeing accounting, compliance and finance operations. He joined in 2023 after CFO roles at Acronis and Wallarm, with earlier experience at Solid Biosciences, Syros, GlassHouse and EY. His published biography describes more than 20 years in accounting and finance.

Richard Jenkins is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sheba Dunston is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Eric Elenko PhD is PureTech’s co-founder and its published acting CEO of Gallop Oncology. His work includes discovery, fundraising and co-founding Seaport Therapeutics, with contributions to programs that became EndeavorRx, Plenity and Cobenfy. Previously a McKinsey consultant, he studied biology at Swarthmore and biomedical sciences at UC San Diego.

Da-Yu Wu is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Kiran Vemuri is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Robert Lyne is PureTech Health’s CEO and board director, appointed permanently on December 18, 2025 after serving as interim CEO since July 2025. He previously led Arix Bioscience and worked at Touchstone Innovations and Bird & Bird. He holds degrees from Oxford and Oxford Brookes; PureTech reports his involvement in more than 80 venture financings.

John Satterlee is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sunila Nair is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Holly Moore is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Yu Lin is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Kathleen Borgmann is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Raul Mandler is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Therapeutics and Medical Consequences. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Guifang Lao is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Therapeutics and Medical Consequences. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Mary Kautz is named by the National Institute on Drug Abuse as DNB lead, Tobacco Regulatory Science Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shang-Yi Tsai is named by the National Institute on Drug Abuse as Director, Integrative Neuroscience Branch (Anne Tsai). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Vani Pariyadath is named by the National Institute on Drug Abuse as Director, Behavioral Cognitive Neuroscience Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Jonathan Pollock is named by the National Institute on Drug Abuse as Director, Genetics, Epigenetics and Development Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Subramaniam Ananthan is named by the National Institute on Drug Abuse as Director, Chemistry Pharmacology Branch (Sam Ananthan). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Ernestine Lenteu is named by the National Institute on Drug Abuse as Program Specialist, OTIPI. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Boris Sabirzhanov is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — HEAL Initiative. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Tam Nguyen is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — pharmacotherapeutic and translational research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Jessica Lukacs is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — business development (published Jess Lukacs). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sara Lioi is named by the National Institute on Drug Abuse as OTIPI translational initiatives staff — drug discovery, challenges and prizes. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Yordan Kostov is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — diagnostics and medical devices. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Saravanan Karuppagounder is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — therapeutics and biomarkers. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Morris Flood is named by the National Institute on Drug Abuse as OTIPI SBIR/STTR programme staff — research tools, wellness and training. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Leonardo Angelone is named by the National Institute on Drug Abuse as OTIPI medical devices programme; NIH Blueprint Medtech programme lead. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Elena Koustova is named by the National Institute on Drug Abuse as Director, OTIPI; Principal Small Business Program Manager. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Rachel Kelley is named by the National Institute on Drug Abuse as Scientific Program Analyst, HEAL Initiative Research Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Aminul Islam is named by the National Institute on Drug Abuse as Health Scientist Administrator, HEAL Initiative Research Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Michele Rankin is named by the National Institute on Drug Abuse as Director, HEAL Initiative Research Program. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shannon Mitchell is named by the National Institute on Drug Abuse as Deputy Chief, Prevention Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Amy Goldstein is named by the National Institute on Drug Abuse as Chief, Prevention Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shelly Su is named by the National Institute on Drug Abuse as Deputy Chief, Treatment and Recovery Services Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Tisha Wiley is named by the National Institute on Drug Abuse as Chief, Treatment and Recovery Services Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

MeLisa Creamer is named by the National Institute on Drug Abuse as Deputy Chief, Epidemiology Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Marsha Lopez is named by the National Institute on Drug Abuse as Chief, Epidemiology Research Branch. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Bethany Deeds is named by the National Institute on Drug Abuse as Deputy Director, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Carlos Blanco is named by the National Institute on Drug Abuse as Director, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Monglan Le is named by the National Institute on Drug Abuse as Correspondence Systems Coordinator. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Marie Lafontant is named by the National Institute on Drug Abuse as Staff Assistant to the Associate Director for Management. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Ellie Johnson is named by the National Institute on Drug Abuse as Supervisory Staff Assistant. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Poorti Khosla is named by the National Institute on Drug Abuse as Staff Assistant to the Deputy Director. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Hilda Schulke is named by the National Institute on Drug Abuse as Staff Assistant to the Director. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Thomas Clarke is named by the National Institute on Drug Abuse as Chief of Staff (published as Tom Clarke). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Shkeda Johnson-Young is named by the National Institute on Drug Abuse as Deputy Executive Officer. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Nathaniel Davis is named by the National Institute on Drug Abuse as Executive Officer. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Wilson M. Compton, M.D., M.P.E., is NIDA deputy director. His official biography describes scientific leadership over NIDA’s research portfolio, prevention, treatment and health consequences of drug use. He previously directed the Division of Epidemiology, Services and Prevention Research from 2002 to 2013. Current directorate listings and 2026 council material corroborate this institutional role; no personal company investment is inferred.

Nora D. Volkow, M.D., is the director of NIDA. Her official biography describes a research psychiatrist and brain-imaging scientist whose work helped establish drug addiction as a disease of the brain. She became NIDA director in May 2003. The current official leadership page and May 2026 council minutes verify her ongoing institute leadership. Funding decisions and specific company award amounts are separate from this personnel role.

Roland A. Owens serves as NIH Acting Deputy Director for Intramural Research. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Jon R. Lorsch serves as NIH Deputy Director for Extramural Research. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Alfred C. Johnson serves as NIH Deputy Director for Management. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Nicole C. Kleinstreuer serves as NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Matthew J. Memoli serves as NIH Principal Deputy Director. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Jay Bhattacharya serves as NIH Director. This current federal biomedical research agency role is verified by the official NIH leadership directory and individual biography. The agency supports basic, clinical and translational research; a leadership appointment does not establish a personal grant or private-company investment.

Published on the company website as Thorvald Steen; the official register gives Thorvald Helmen Steen.

Published on the company website as Jon H Ulvensøen; the official register gives Jon Herman Ulvensøen.

The company website lists him as director, but he is absent from the current official company register. Current tenure is unconfirmed.

The company website lists him as chairman, but the current official registry names Tom Austad instead. This published affiliation does not establish a current directorship.

OculAudio publishes the title CSMFO without expanding the acronym.

Hearing-industry executive trained in acoustics, with experience at ExSilent, Varibel Innovations and Otoharmonics.

Norwegian entrepreneur who founded OculAudio in 2017; experienced in telecommunications business development. The official current registry lists him as board chairman, superseding the differing chairman shown on the undated company team page.

Physician and professor, published on MedStorm’s advisory board.

Uppsala University neonatal intensive-care physician and professor.

University of Oslo physician and professor.

Previously an executive vice president for EMEA and APAC at Senzime; published as an associated adviser.

Professor in electrical engineering, media and computer science, published as an associated adviser.

Advises on electrical engineering and software development.

Advises on regulatory technical issues and regulatory affairs.

Engineer with training at the Norwegian University of Science and Technology and Norwegian School of Economics.

Quality auditor experienced in ISO, GMP, HACCP and quality assurance.

Engineer working on software and technical development.

Published by MedStorm as Jens Gran; the official registry gives Jens Otto Gran. Civil engineer with finance training and experience in product development, entrepreneurship and project financing.

Physician and University of Oslo researcher who invented MedStorm’s skin-conductance approach to pain and nociception assessment.

Venture investor with prior experience at Forté Ventures and Siemens Venture Capital.

AI technologist and entrepreneur; previously a DARPA Biological Technologies Office program manager and founder of MobiTV and MicroDisplay Corporation.

Steven Ju is a head of legal at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Hyeseong Lee is a assistant manager at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Blaire Yoo is a manager at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Jinlee Ok is a senior manager at Sazze Partners, according to the manager’s current public operations team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Gihun Choi is a associate at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Grace Kim is a associate at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Ukjin (Jay) Kwon is a principal at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Kathy Ku is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Ohsang Kwon is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Do Gyun Guen is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Sukhyun Kim is a venture partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea. The public website labels his affiliation Venture Partner; the April2026 adviser filing separately lists Sukhyun Kim as managing partner, status acquired October2021. These differing primary-source labels are retained without inferring employment or a departure date.

Eun Soo Park is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea.

Greg Kwangrog Kim is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea. The April2026 adviser filing names Kwangrog Kim CFO and managing partner, with the status acquired inJune2018; the FundII SEC filing gives the full name Greg Kwangrog Kim.

Kiha Lee is a partner at Sazze Partners, according to the manager’s current public investment team directory. The firm works with early-stage and growth companies across the United States and South Korea. The April2026 adviser filing additionally names Kiha Lee CEO and managing partner, with the status acquired inJune2018.

Geunbae Jang is an independent director of SKNetworks, named in its current official governance directory with a March2025 appointment month. The company’s biography identifies him as an accounting professor at HandongGlobalUniversity and describes finance, strategy and advisory experience at DoosanBobcat, construction-equipment finance leadership at DoosanInfracore and AsiaPacific financial-control work at eBay. He serves on SKNetworks’ human-resources committee, contributing finance and accounting oversight. No company operating investment title or personal subscription is inferred.

Healthcare investor, strategist and operator focused on biopharmaceuticals, medical devices, services and technology. He evaluates and manages healthcare investments and advises companies on financing, strategy and product development. Previously he led Parsolex GMP Center and he serves as vice chair of the CUNY School of Public Health Foundation.

Physician and healthcare investor leading Relativity Healthcare Partners. He serves on Ansun Biopharma’s board and has worked with emerging drug and medical-device companies. His medical training includes an MD at UC Irvine and biology studies at the University of Pennsylvania.

Greek venture investor who launched Velocity Partners in 2018, co-founded Found.ation and SocialInnov, and founded TEDxAthens. He is also a founding partner of the separate Apeiron Ventures firm.

Michelle Floyd-Rebollo, MD, is a pediatrician with United States and Spain experience, integrative-health training and interests in child development and mental health. HYM names her in its employee listing, and her own 2025 post describes presenting HYM teletherapy outcome data. Her current principal clinic biography is at Empower U; an undated third-party HYM medical-director title is not treated as confirmed current employment.

Angela Fontenot is named in Healthy Young Minds’ public employee listing, and her own professional profile identifies the company as her affiliation. Her exact job title and detailed current responsibilities are not published in the accessible primary sources.

Jonathan Shambroom is Healthy Young Minds’ COO, identified in his Supernova founder-community biography and corroborated by his own current professional profile and HYM employee listing. He has held operating and product leadership roles at technology startups and worked in seed investment operations.

Michael Kornberg, MD, is identified by Healthy Young Minds as a child and adolescent psychiatrist in its published educational material on social-skills groups. His clinical affiliation is recorded with that source; a complete current appointment or employment history is not publicly established.

Michelle L. Zube, MA, BCBA, is identified in HYM educational articles as behavioral therapy lead. A 2022 professional event biography describes licensed behavior-analysis and teaching qualifications, telehealth, parent training and Acceptance and Commitment Training. Current tenure beyond the live published affiliation is not independently dated.

Julie D’Orsi is identified in Healthy Young Minds’ published educational articles as lead psychometrist, discussing psychological evaluations, executive function and school accommodations. The company’s current public LinkedIn employee listing also names her. No full appointment date is disclosed.

Susanne Graf, ATR-BC, LCAT, MFA, leads art therapy at Healthy Young Minds. Her own 2023 Vail board application describes leading its multistate teletherapy art-therapy team and co-founding Vail Mind Center. HYM’s service page spells her first name Susanna; her application and other HYM articles identify Susanne.

Julie Norman is identified on Healthy Young Minds’ current speech and language therapy page as chief therapeutic officer. A speech-language pathologist, she was described as a lead therapist in earlier HYM educational articles. No exact promotion date is published.

Cari Whitlock, PsyD, leads pediatric psychologists at Healthy Young Minds. Her specialties include pediatric neuropsychology, trauma and forensic evaluations. She has trained psychologists and social workers through Department of Defense and VA work, cared for children with neurological conditions and researched ADHD.

Paul Graf is the founder and CEO of Healthy Young Minds. His earlier technology entrepreneurship and investment work preceded founding Vail Mind Center in Edwards, Colorado. Experience shifting that clinic to teletherapy during COVID-19 inspired HYM’s multidisciplinary pediatric care model and focus on Medicaid access.

AD Mohanraj is vice president of engineering at City Light Capital, as identified in the firm’s current public team directory.

Rohan Nair is head of product at City Light Capital, as identified in the firm’s current public team directory.

Grace Cushman is senior vice president of operations at City Light Capital, as identified in the firm’s current public team directory.

Jeff Rinehart is a partner at City Light Capital. The firm’s current public directory identifies him as one of its two partners; the firm invests in technology-led care, climate and education businesses.

Josh Cohen is a partner and co-founder of City Light Capital, focused on technology investments with measurable social impact. A published2020 Water Innovation Advisors biography describes earlier family-office investing, venture/private-debt work and technology-company business development. Its historical outside board/adviser affiliations are not asserted as current appointments. He is distinct from the later Innovation Endeavors investor also named Josh Cohen.

Hwajin Chang is an independent director of SKNetworks and chair of its human-resources committee. Its own current board biography lists leadership experience including president of APAC at Cohere, president of ConfluentKorea and GoogleCloudKorea, MicrosoftAsiaPacific strategy leadership and CEO/president of IBMKorea. That background supports his technology and AI expertise on the board; previous outside leadership titles are not all treated as simultaneous current positions. The company lists his board appointment month as March2024.

Moonyoung Lee is an independent director of SKNetworks, according to its current governance directory. The company identifies her accounting expertise through an associate professorship at DuksungWomen’sUniversity and public-service experience with the FinancialServicesCommission and Dobong-gu financial-plan deliberations. She participates in the board’s strategy and ESG oversight. The current directory gives an initial2021 appointment and a2024 reappointment month; no undisclosed exact employment day or payroll position is inferred.

Sooil Chai is the independent chair of SKNetworks’ board of directors, as listed in the company’s current public governance directory. He chairs its strategy and ESG committee, overseeing corporate strategy and long-term sustainability alongside the board’s investment and risk responsibilities. The company identifies his earlier professional background in financial-institution work at BostonConsultingGroup in AsiaPacific. The independent board chair role is distinct from the company’s CEO and operational management.

Keedong Kim is a nonexecutive director of SK Networks, named in its current official governance directory and shareholder voting records. The company’s sustainability report identifies his wider professional background in SKInc.finance leadership and previous management-support and finance responsibilities at SKChemicals. His SKNetworks duties include board oversight and membership of its human-resources and strategy/ESG committees. This is a nonexecutive governance appointment, not a claim that he is a full-time SKNetworks investment employee.

Sunghwan Choi is an executive director of SK Networks and is identified in its own2025 AIWAVE announcement as president and chief operating officer. He has presented the company’s AI strategy and led its engagement with global technology and investment partners. The company’s report lists earlier responsibilities in business leadership, planning, the HappinessDesignCenter and strategic planning, along with SKInc.business-model innovation work. His board affiliation is separate from his operating executive capacity and is not evidence of a personal financing ticket.

Hojeong Lee is CEO and president of SK Networks, independently confirmed by the company’s current2026 CEO message and public board directory. He leads the listed operating holding company’s transition toward AI services and strategic portfolio management. Its own sustainability report describes previous responsibilities as president, head of management support and new growth at SKNetworks, and director of InvestmentCenter2 at SKInc. His corporate leadership is distinct from a personal investor identity. The governance page uses several romanisations of his name and includes older appointment metadata; no precise current reappointment or departure day is inferred.

Jonny He, CPA is the CFO named in Eckuity LLC’s March 30, 2026 ADV and Eckuity Capital Management LLC’s April 3, 2026 ADV. His public professional profile republishes Eckuity’s joint CFO/COO appointment. The newer platform directory lists Ken Eagle as CFO and Ryan Green as COO; Jonny’s role is scoped to those dated filings and earlier appointment, with no guessed departure date. His public profile uses a generic avatar, so no substitute portrait is imported.

Vishal Jain co-founded Eckuity with Youssef Sebban according to its February 2024 final-close announcement. The March 30, 2026 Eckuity LLC ADV still lists him as managing partner and control owner. He is absent the newer public platform directory; this does not establish that his Fund I legal position ended. FINRA’s current BrokerCheck reports his Eckuity managing-partner activity since March 2021. Exact employment end date and authentic portrait remain unverified.

John Hood is advisory board at Eckuity Capital. Biotechnology entrepreneur and Endeavor BioMedicines co-founder. His Impact Biomedicines transaction included contingent milestones, so its maximum headline value is not treated as closed investment cash.

Manuel Hidalgo Medina is advisory board at Eckuity Capital. Oncology researcher and public-company director. Bristol Myers Squibb’s 2026 proxy dates his Weill Cornell professorship and division-chief tenure to 2019–2025; Eckuity’s older Cornell headline is qualified accordingly.

Hocine Sidi-Said is advisory board at Eckuity Capital. Healthcare entrepreneur who co-founded KELIX bio; contributes pharmaceutical-platform development and international healthcare experience. Exact current outside executive position is not inferred from an older headline.

Diane Simeone is advisory board at Eckuity Capital. Surgeon-scientist and UC San Diego Moores Cancer Center director contributing oncology research and clinical-development expertise.

Tom Schoenherr is advisory board at Eckuity Capital. Genetics and diagnostics executive associated with Ambry Genetics. Eckuity labels his CEO affiliation historical, while Ambry’s own directory still lists him as CEO; no inferred employment end date is recorded.

Francois Sarkozy is advisory board at Eckuity Capital. Physician and FSNB Health & Care founder contributing healthcare strategy and institutional relationships; distinct from his brother Nicolas Sarkozy.

Daniel Vial is venture partner at Eckuity Capital. Healthcare policy and market-access adviser. This is the pharmaceutical-sector Daniel Vial linked by Eckuity, not the similarly named sports journalist.

Frederic Gilg is venture partner at Eckuity Capital. Healthcare investment and strategy professional associated with GA Partners; contributes operational and market analysis.

Michael Rossbach is venture partner at Eckuity Capital. Genomics scientist and Axiom-Insights founder with experience at the Genome Institute of Singapore and Vela Diagnostics; contributes precision-medicine and diagnostic expertise.

Abderrahim Mahfoudi is venture partner at Eckuity Capital. Biotechnology scientist and research executive contributing therapeutic development and translational-research expertise.

Lokman Ouijdani is venture partner at Eckuity Capital. Healthcare transaction and investment adviser with experience in international strategy and market expansion.

Richard Pasternak is venture partner at Eckuity Capital. Cardiologist and former Merck clinical-development executive contributing cardiovascular therapeutic-development expertise.

Natalya McLane directs product management at Neurala. Her software career spans on-premises products, SaaS and computer vision, including product strategy and coordination across technical teams. She holds bachelor’s and master’s degrees in computer science and has completed additional management coursework.

Dee Athwal is venture partner at Eckuity Capital. Biologics and antibody-development executive, also known as Diljeet Singh Athwal; Amethyst Pharma publishes his named consultant biography. Eckuity’s Complement CEO headline is older than Complement’s current directory.

Larry Florin is venture partner at Eckuity Capital. Clinical-research executive, also known as Lawrence Florin, appointed Hesperos CEO in 2024; contributes drug-development and microphysiological-systems experience.

Jean-Raymond Raynal, also called JR, is an engineering manager at Neurala. Over more than a decade at the company he progressed from engineering intern to leading software teams and building core vision infrastructure. He studied computer science and robotics at ENSEIRB-MATMECA, part of Bordeaux INP.

Named to Sarcura’s advisory board in April 2022. The appointment article describes cell therapy manufacturing and automation work at Takeda, Torque Therapeutics and Novartis, including Kymriah process development. Holds an MIT doctorate in aerospace engineering. These are source-dated career details; continued 2026 advisory tenure is not independently established.

Named to Sarcura’s advisory board in April 2022. The appointment article describes technical operations and cell and gene therapy leadership at Orchard Therapeutics and Novartis. Holds a doctorate in pharmaceutical technologies from the University of Pavia. These are source-dated career details; continued 2026 advisory tenure is not independently established.

Named to Sarcura’s advisory board in August 2024. His career includes product development at Sartorius and the CTO role at IntelliCyt. Holds a doctorate in microbiology and immunology from Creighton University. Continued 2026 tenure is not independently established by the dated appointment article.

Sarcura co-founder and chief scientific officer leading application development. Previously led stem-cell technology research teams at Fraunhofer and worked on cell therapy at GEA. Holds a doctorate from the University of the Saarland medical faculty and a biology diploma from TU Darmstadt.

Sarcura CTO leading development of cell and gene therapy manufacturing equipment. Previously worked in research, programs and development at Illumina, Schott and EV Group. Holds an MBA in Biotechnology and Pharmaceutical Management and an engineering degree in chemical engineering.

Sarcura co-founder and CEO, responsible for company strategy and resources. Previously worked in innovation and business development at GEA, Parker Hannifin and Pall. Holds an MBA in Innovation & Entrepreneurship from WU Executive Academy and an engineering degree in biochemistry, biotechnology and genetics.

Gertjan Bartlema is venture partner at Eckuity Capital. International biotechnology executive and Populus Bio co-founder. Populus’s own biography describes his Vico Therapeutics CEO position as previous, qualifying the older Eckuity headline.

Matt Luciw directs Neurala’s AI research, including efficient computer vision, industrial inspection and adaptive learning on constrained devices. He joined the company in 2014 after postdoctoral work at IDSIA in Switzerland and completed a PhD in computer science at Michigan State University. His research background includes numerous peer-reviewed publications and collaboration with engineering teams to bring machine learning into products.